{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:18:24Z","timestamp":1789676304120,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s11095-014-1451-y","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T21:51:34Z","timestamp":1406065894000},"page":"144-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children"],"prefix":"10.1007","volume":"32","author":[{"name":"and the CRESim & Epi-CRESim Project Groups","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayode","family":"Ogungbenro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,23]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","volume":"31","author":"DL Hurst","year":"1990","unstructured":"Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia. 1990;31:397\u2013400.","journal-title":"Epilepsia"},{"key":"1451_CR2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jpeds.2010.10.035","volume":"158","author":"RP Morse","year":"2011","unstructured":"Morse RP. Dravet syndrome: inroads into understanding epileptic encephalopathies. J Pediatr. 2011;158:354\u20139.","journal-title":"J Pediatr"},{"issue":"Suppl 2","key":"1451_CR3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","volume":"52","author":"C Chiron","year":"2011","unstructured":"Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52 Suppl 2:72\u20135.","journal-title":"Epilepsia"},{"key":"1451_CR4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40263-012-0004-3","volume":"26","author":"GL Plosker","year":"2012","unstructured":"Plosker GL. Stiripentol: in severe myoclonic epilepsy of infancy (dravet syndrome). CNS Drugs. 2012;26:993\u20131001.","journal-title":"CNS Drugs"},{"key":"1451_CR5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638\u201342.","journal-title":"Lancet"},{"key":"1451_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-198308030-00003","volume":"8","author":"DJ Greenblatt","year":"1983","unstructured":"Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1983;8:233\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"1451_CR7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279\u201386.","journal-title":"Drug Metab Dispos"},{"key":"1451_CR8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2125.1981.tb01281.x","volume":"12","author":"DJ Greenblatt","year":"1981","unstructured":"Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Clobazam kinetics in the elderly. Br J Clin Pharmacol. 1981;12:631\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","volume":"4","author":"C Chiron","year":"2007","unstructured":"Chiron C. Stiripentol Neurother. 2007;4:123\u20135.","journal-title":"Stiripentol Neurother"},{"key":"1451_CR10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0090-9556(25)08990-1","volume":"14","author":"TA Moreland","year":"1986","unstructured":"Moreland TA, Astoin J, Lepage F, Tombret F, Levy RH, Baillie TA. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14:654\u201362.","journal-title":"Drug Metab Dispos"},{"key":"1451_CR11","first-page":"24","volume":"23","author":"S Chhun","year":"2009","unstructured":"Chhun S, Peigne S, Rey E, Pons G, Jullien V. Population pharmacokinetic study in healthy volunteers treated with 3 single doses of stiripentol (500, 1,000, 2,000\u00a0mg). Fundam Clin Pharmacol. 2009;23:24\u20135.","journal-title":"Fundam Clin Pharmacol"},{"key":"1451_CR12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","volume":"23","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23:523\u201333.","journal-title":"J Clin Pharmacol"},{"key":"1451_CR13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608\u201311.","journal-title":"Drug Metab Dispos"},{"key":"1451_CR14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, Rousseau M, d\u2019Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62:490\u2013504.","journal-title":"Clin Pharmacol Ther"},{"key":"1451_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","volume":"36","author":"RH Levy","year":"1984","unstructured":"Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1451_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP. 2002;32:1\u2013277.","journal-title":"Ann ICRP"},{"key":"1451_CR17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","volume":"93","author":"GB Haycock","year":"1978","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62\u20136.","journal-title":"J Pediatr"},{"key":"1451_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D DuBois","year":"1916","unstructured":"DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863\u201371.","journal-title":"Arch Intern Med"},{"key":"1451_CR19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931\u201356.","journal-title":"Clin Pharmacokinet"},{"key":"1451_CR20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238\u201357.","journal-title":"J Pharm Sci"},{"key":"1451_CR21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259\u201376.","journal-title":"J Pharm Sci"},{"key":"1451_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225\u201337.","journal-title":"AAPS J"},{"key":"1451_CR23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1528-1157.1984.tb03448.x","volume":"25","author":"RH Levy","year":"1984","unstructured":"Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia. 1984;25:486\u201391.","journal-title":"Epilepsia"},{"key":"1451_CR24","doi-asserted-by":"crossref","unstructured":"Rey E, Jullien V, D\u2019Athis P, Vincent J, Pons G. Is pharmacokinetics of stiripentol linear? Clin Pharmacol Ther. 2005;77:P64\u20134.","DOI":"10.1016\/j.clpt.2004.12.134"},{"key":"1451_CR25","volume-title":"NONMEM User\u2019s guides. (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User\u2019s guides. (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"key":"1451_CR26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2125.1987.tb03073.x","volume":"23","author":"G Menke","year":"1987","unstructured":"Menke G, Pfister P, Sauerwein S, Rietbrock I, Woodcock BG, Rietbrock N. Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods. Br J Clin Pharmacol. 1987;23:439\u201345.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR27","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1208\/ps040104","volume":"4","author":"PJ McNamara","year":"2002","unstructured":"McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4:E4.","journal-title":"AAPS PharmSci"},{"key":"1451_CR28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jcph.100","volume":"53","author":"F Salem","year":"2013","unstructured":"Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol. 2013;53:857\u201365.","journal-title":"J Clin Pharmacol"},{"key":"1451_CR29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.284.5420.1677","volume":"284","author":"GB West","year":"1999","unstructured":"West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677\u20139.","journal-title":"Science"},{"key":"1451_CR30","unstructured":"GetData Graph Digitizer, http:\/\/getdata-graph-digitizer.com\/2013 ."},{"key":"1451_CR31","unstructured":"MATLAB 7.14.0.739. Natick, Massachusetts: The MathWorks Inc. R 2012a."},{"key":"1451_CR32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.1981.tb01180.x","volume":"11","author":"G Tedeschi","year":"1981","unstructured":"Tedeschi G, Riva R, Baruzzi A. Clobazam plasma-concentrations - pharmacokinetic study in healthy-volunteers and data in epileptic patients. Br J Clin Pharmacol. 1981;11:619\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF00542148","volume":"26","author":"HR Ochs","year":"1984","unstructured":"Ochs HR, Greenblatt DJ, Luttkenhorst M, Verburg-Ochs B. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol. 1984;26:499\u2013503.","journal-title":"Eur J Clin Pharmacol"},{"key":"1451_CR34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/jps.2600691131","volume":"69","author":"DJ Greenblatt","year":"1980","unstructured":"Greenblatt DJ. Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. J Pharm Sci. 1980;69:1351\u20132.","journal-title":"J Pharm Sci"},{"key":"1451_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/j.1552-4604.1982.tb05711.x","volume":"22","author":"M Divoll","year":"1982","unstructured":"Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J Clin Pharmacol. 1982;22:69\u201373.","journal-title":"J Clin Pharmacol"},{"key":"1451_CR36","first-page":"287","volume":"24","author":"H Bun","year":"1986","unstructured":"Bun H, Coassolo P, Gouezo F, Serradimigni A, Cano JP. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24:287\u201393.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"1451_CR37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-198308010-00005","volume":"8","author":"DJ Greenblatt","year":"1983","unstructured":"Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clin Pharmacokinet. 1983;8:83\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"1451_CR38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.1987.tb03051.x","volume":"23","author":"T Pullar","year":"1987","unstructured":"Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23:317\u201321.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2125.1984.tb02558.x","volume":"18","author":"S Jawad","year":"1984","unstructured":"Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol. 1984;18:873\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1552-4604.1980.tb01717.x","volume":"20","author":"JJ Vallner","year":"1980","unstructured":"Vallner JJ, Kotzan JA, Stewart JT, Honigberg IL, Needham TE, Brown WJ. Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects. J Clin Pharmacol. 1980;20:444\u201351.","journal-title":"J Clin Pharmacol"},{"key":"1451_CR41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","volume":"34","author":"TW May","year":"2012","unstructured":"May TW, Boor R, Mayer T, Jurgens U, Rambeck B, Holert N, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34:390\u20137.","journal-title":"Ther Drug Monit"},{"key":"1451_CR42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002280050147","volume":"50","author":"A Tran","year":"1996","unstructured":"Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d\u2019Athis P, Chiron C, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol. 1996;50:497\u2013500.","journal-title":"Eur J Clin Pharmacol"},{"key":"1451_CR43","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, Rey E, Blehaut H, d\u2019Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618\u201326.","journal-title":"Epilepsia"},{"key":"1451_CR44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","volume":"15","author":"AR Maharaj","year":"2013","unstructured":"Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455\u201364.","journal-title":"AAPS J"},{"key":"1451_CR45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2125.1987.tb03247.x","volume":"24","author":"T Pullar","year":"1987","unstructured":"Pullar T, Haigh JR, Peaker S, Feely MP. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol. 1987;24:793\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/j.1552-4604.1978.tb01600.x","volume":"18","author":"JJ Vallner","year":"1978","unstructured":"Vallner JJ, Needham TE, Jun HW, Brown WJ, Stewart JT, Kotzan JA, et al. Plasma levels of clobazam after three oral dosage forms in health subjects. J Clin Pharmacol. 1978;18:319\u201324.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"1451_CR47","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","volume":"7","author":"W Rupp","year":"1979","unstructured":"Rupp W, Badian M, Christ O, Hajdu P, Kulkarni RD, Taeuber K, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7 Suppl 1:51S\u20137S.","journal-title":"Br J Clin Pharmacol"},{"key":"1451_CR48","unstructured":"L. Inc. Onfi (clobazam) Tablets for oral use: prescribing information 2011."},{"issue":"Suppl 1","key":"1451_CR49","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","volume":"7","author":"M Volz","year":"1979","unstructured":"Volz M, Christ O, Kellner HM, Kuch H, Fehlhaber HW, Gantz D, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7 Suppl 1:41S\u201350S.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1451-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1451-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1451-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:21:40Z","timestamp":1746310900000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1451-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,23]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1451-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,23]]}}}